Researchers identify 49 genes that work differently in schizophrenia patients - <em>News Release</em>
Imperial College London News Release
Under strict embargo for
08.30 am GMT / 03.30 am EST
Tuesday 3 March 2009
Schizophrenia could be caused by faulty signalling in the brain, according to new research published today in the journal Molecular Psychiatry. In the biggest study of its kind, scientists looking in detail at brain samples donated by people with the condition have identified 49 genes that work differently in the brains of schizophrenia patients compared to controls.
Many of these genes are involved in controlling cell-to-cell signalling in the brain. The study, which was carried out by researchers at Imperial College London and GlaxoSmithKline, supports the theory that abnormalities in the way in which cells ‘talk’ to each other are involved in the disease.
Schizophrenia is thought to affect around one in 100 people. Symptoms vary but can include hallucinations, lack of motivation and impaired social functioning. The disorder has little physical effect on the brain and its causes are largely unknown.
Schizophrenia could be caused by faulty signalling in the brain
Some scientists believe that schizophrenia could be caused by the brain producing too much dopamine, partly because drugs that block dopamine action provide an effective treatment for the condition. Another theory is that the coat surrounding nerve cells, which is made of myelin, is damaged in people with schizophrenia. However, the new study found that the genes for dopamine and for myelin were not acting any differently in schizophrenia patients compared with controls.
Professor Jackie de Belleroche, the corresponding author of the paper form Imperial College London said: “The first step towards better treatments for schizophrenia is to really understand what is going on, to find out what genes are involved and what they are doing. Our new study has narrowed the search for potential targets for treatment.”
As well as pointing towards signalling as the cause of schizophrenia, the new findings could also lead to new ways of diagnosing the condition. At the moment, patients are diagnosed on the basis of their behaviour.
“Most patients are diagnosed as teenagers or in their early 20s, but if they could be diagnosed earlier, they could be treated more effectively and they could have a better quality of life. To have the possibility of transforming someone’s life early on instead of having to take drugs indefinitely would be wonderful,” added Professor de Belleroche.
The researchers reached their conclusions after analysing brain tissue from 23 controls and 28 schizophrenia patients, selected from brains donated by UK patients being treated for schizophrenia and comparing the data to an equivalent study in the USA. The changes described in this study were common to both studies. This is the biggest cohort of schizophrenia patients used for this type of study to date.
This is part of a larger study looking at proteins and DNA as well as mRNA in the samples, which were taken from two brain regions associated with schizophrenia: the frontal cortical area and the temporal cortex. mRNA are copies of small sections of our DNA that cells use to build proteins. Unlike DNA, mRNA varies in different parts of the body, where different proteins are needed.
The research was possible due to a successful collaboration between Imperial College and GlaxoSmithKline.
-ENDS-
For further information please contact:
Lucy Goodchild
Press Officer
Imperial College London
e-mail: lucy.goodchild@imperial.ac.uk
Telephone: +44 (0)20 7594 6702 or ext. 46702
Out of hours Duty Press Officer: +44 (0)7803 886 248
Notes to editors:
1. “Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function” Molecular Psychiatry, 3 March 2009
Corresponding author: Professor J de Belleroche
(For a full list of authors please see paper.)
2. About Imperial College London
Consistently rated amongst the world's best universities, Imperial College London is a science-based institution with a reputation for excellence in teaching and research that attracts 12,000 students and 6,000 staff of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and business, delivering practical solutions that improve quality of life and the environment - underpinned by a dynamic enterprise culture.
Since its foundation in 1907, Imperial's contributions to society have included the discovery of penicillin, the development of holography and the foundations of fibre optics. This commitment to the application of research for the benefit of all continues today, with current focuses including interdisciplinary collaborations to improve health in the UK and globally, tackle climate change and develop clean and sustainable sources of energy.
Website:www.imperial.ac.uk
Article text (excluding photos or graphics) available under an Attribution-NonCommercial-ShareAlike Creative Commons license.
Photos and graphics subject to third party copyright used with permission or © Imperial College London.
